Disposition of 977 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 37.4556 subject to Rule 16b-3
| COLL Stock | USD 30.50 0.21 0.68% |
About 62% of Collegium Pharmaceutical's investor base is looking to short. The analysis of overall sentiment of trading Collegium Pharmaceutical stock suggests that many investors are alarmed at this time. Collegium Pharmaceutical's investing sentiment shows overall attitude of investors towards Collegium Pharmaceutical.
Collegium |
Filed transaction by Collegium Pharmaceutical Officer: Evp And General Counsel. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Collegium Pharmaceutical Fundamental Analysis
We analyze Collegium Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Collegium Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Collegium Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Collegium Pharmaceutical is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Collegium Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Collegium Pharmaceutical stock to make a market-neutral strategy. Peer analysis of Collegium Pharmaceutical could also be used in its relative valuation, which is a method of valuing Collegium Pharmaceutical by comparing valuation metrics with similar companies.
Peers
Collegium Pharmaceutical Related Equities
| RGC | Regencell Bioscience | 5.51 | ||||
| PCRX | Pacira BioSciences, | 1.62 | ||||
| PBH | Prestige Brand | 0.71 | ||||
| RDY | Dr Reddys | 0.43 | ||||
| AMPH | Amphastar | 0.04 | ||||
| EOLS | Evolus | 0.80 | ||||
| PAHC | Phibro Animal | 0.93 | ||||
| ALKS | Alkermes Plc | 1.02 | ||||
| ITCI | Intracellular | 1.09 | ||||
| ANIP | ANI Pharmaceuticals | 3.64 | ||||
| PROC | Procaps Group | 27.75 |
Check out Collegium Pharmaceutical Hype Analysis, Collegium Pharmaceutical Correlation and Collegium Pharmaceutical Performance. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.